ArticleOpen forum infectious diseases2026
Thiazolidinedione Use and Risk of Bacterial Enteric Infection Among Adults With Type 2 Diabetes Mellitus.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Thiazolidinediones are peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists commonly used to treat type 2 diabetes mellitus. In experimental models, epithelial PPAR-γ signaling contributes to colonization resistance against bacterial enteric pathogens by shaping oxygen and nitrate luminal bioavailability. Whether the use of PPAR-γ agonists in humans is associated with reduced risk of bacterial enteric infection is unknown. Methods: To investigate whether users of thiazolidinediones (PPAR-γ agonists) have decreased risk of bacterial enteric infection, we performed a retrospective nationwide analysis using the cloud-based TriNetX Analytics Platform which aggregates health records from 117 million patients across 66 US healthcare organizations. We compared the risk of bacterial enteric infection among patients with diabetes prescribed thiazolidinediones, a class of PPAR-γ agonists, compared with users of other glucose-lowering medications. Results: Among 85 916 thiazolidinedione users categorized as being at low risk for bacterial enteric infection (no prior history of infection) and 1974 persons identified as being at high risk (prior history of bacterial enteric infection), the risk of bacterial enteric infection was reduced by 49% (RR 0.51, 95% confidence interval [CI] .32-.82) and 22% (RR 0.78, 95% CI .69-.88) respectively, compared to users of other glucose-lowering medications. This reduction in risk was consistent among high-risk individuals, regardless of sex or age. Similar results were observed in high-risk patients when thiazolidinedione users were directly compared to those on DPP-4 inhibitors. Conclusions: These findings demonstrate an association between PPAR-γ agonist use and a reduced risk of bacterial enteric infection and support further clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.